交易中 09-24 10:02:27 美东时间
-1.795
-0.59%
Acuity Inc. (NYSE:AYI) will release its fourth-quarter earnings report before the opening bell on Thursday, Oct. 1. Analysts expect the Atlanta, Georgia-based company to report quarterly earnings of $5.66 per share, up from $5.20 per share in the year-ago period. The consensus estimate for AYI’s qua...
09-23 20:57
Acuity (NYSE:AYI) has outperformed the market over the past 20 years by 1.14% on an annualized basis producing an average annual return of 10.28%. Currently, Acuity has a market capitalization of $9.47 billion. Buying $100 In AYI: If an investor had bought $100 of AYI stock 20 years ago, it would be...
09-11 06:45
EyePoint, Inc. will participate in several upcoming conferences, including the Citi 2026 Biopharma Back to School Conference on September 9, 2026, the Cantor Global Healthcare Conference 2026 on September 10, 2026, and the Morgan Stanley Global Healthcare Conference on September 15, 2026. Fireside chats from these events will be available on the Company’s website. Additionally, EyePoint will present at The Retina Society 59th Annual Scientific Me...
09-02 11:00
Acuity (NYSE:AYI) has outperformed the market over the past 20 years by 1.38% on an annualized basis producing an average annual return of 10.6%. Currently, Acuity has a market capitalization of $10.03 billion. Buying $1000 In AYI: If an investor had bought $1000 of AYI stock 20 years ago, it would ...
08-29 07:30
Acuity Inc. (NYSE: AYI) will release its fiscal 2026 fourth-quarter and full-year results on October 1, 2026, at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET led by CEO Neil Ashe. The earnings release, webcast, and presentation will be available on the Investor Relations section of the Company's website at www.investors.acuityinc.com. A replay of the call will be available shortly after the event. Acuity Inc., based in Atlanta, Geo...
08-28 20:15
Oculis Holding AG has initiated the PIONEER-1 trial to evaluate Privosegtor for optic neuritis (ON), with the first patient treated in the U.S. Privosegtor, a novel neuroprotective agent, showed promising results in the Phase 2 ACUITY trial, leading to FDA Breakthrough Therapy and EMA PRIME designations. The trial aims to assess visual recovery and safety, with potential broader applications in neurology, including acute multiple sclerosis relaps...
08-24 08:00
Acuity Inc. appoints Ruth Gratzke as President of Acuity Brands Lighting (ABL) effective September 1, 2026. With over 25 years of leadership in industrial technology, smart infrastructure, and electrical products, Gratzke joins Acuity from Siemens, where she led businesses in smart buildings, grid-edge technology, and energy infrastructure. Acuity CEO Neil Ashe highlighted her track record in driving growth and building high-performing teams, pos...
08-18 13:00
Acuity (NYSE:AYI) has outperformed the market over the past 20 years by 1.82% on an annualized basis producing an average annual return of 11.13%. Currently, Acuity has a market capitalization of $10.79 billion. Buying $1000 In AYI: If an investor had bought $1000 of AYI stock 20 years ago, it would...
08-13 05:30
美国国防科技公司AeroVironment与物理AI软件公司Applied Intuition于7月29日宣布达成战略合作协议,将共同为美军及其盟友提升无人...
07-29 22:52
美国国防科技公司AeroVironment与物理AI软件公司Applied Intuition于7月29日宣布达成战略合作协议,将共同为美军及其盟友提升无人...
07-29 22:52